USANA Health Sciences (NYSE:USNA) Releases Earnings Results, Beats Estimates By $0.19 EPS

USANA Health Sciences (NYSE:USNA) released its quarterly earnings data on Tuesday. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19, Zacks reports. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded down $0.29 on Tuesday, hitting $20.61. The company’s stock had a trading volume of 103,603 shares, compared to its average volume of 113,000. The company has a market capitalization of $376.75 million, a PE ratio of 23.42, a PEG ratio of 0.95 and a beta of 0.67. The company has a 50-day simple moving average of $20.71 and a 200 day simple moving average of $23.69. USANA Health Sciences has a 1 year low of $18.48 and a 1 year high of $38.32.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on USNA shares. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, USANA Health Sciences has a consensus rating of “Reduce” and an average price target of $36.00.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its position in USANA Health Sciences by 4.6% during the fourth quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after purchasing an additional 542 shares in the last quarter. ExodusPoint Capital Management LP boosted its stake in shares of USANA Health Sciences by 58.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 28,625 shares of the company’s stock valued at $562,000 after purchasing an additional 10,552 shares in the last quarter. Barclays PLC grew its holdings in shares of USANA Health Sciences by 57.9% during the 4th quarter. Barclays PLC now owns 49,271 shares of the company’s stock valued at $967,000 after purchasing an additional 18,068 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences during the 4th quarter valued at $11,485,000. Finally, First Trust Advisors LP purchased a new position in USANA Health Sciences in the 4th quarter worth $246,000. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.